There is one clinical trial.
Latinos have been one of the racial/ethnic groups most impacted by the COVID-19 pandemic, and evidence of effective strategies to curb the pandemic, reduce disparities, and mitigate its impact is lacking and very urgent. The goal of this competitive revision is to expand an ongoing academic-community partnership to adapt, implement, and evaluate a multi-level intervention to mitigate the multi-dimensional toll of COVID19 among Latino immigrant communities in Philadelphia.
Description: The availability and/or usage of five modifiable risk factors: Use of mask, frequent hand washing, compliance with physical distance, ability to isolate, quarantine if needed, will be combined (added) to create a score.Measure: Risk of exposure to COVID-19 Time: 3 months
Description: The availability and/or access to the following 5 factors: Health insurance, regular health care provider, perception that lack of health insurance, money, or immigration status is a barrier for COVID-19 testing and/or care will be combined to create a score.Measure: Access to health care and testing Time: 3 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports